SERES Medical Brings MVision’s Cutting Edge and Guideline-Based AI Segmentation Solution to the Turkish Market

Helsinki – September 6, 2021 – MVision AI, the software service provider for radiotherapy treatment planning, announces a new distribution partnership with SERES Medical, the leading Turkish medical equipment provider. 

The agreement entitled SERES Medical the rights to distribute products and services of MVision AI in Turkey. Both SERES Medical and MVision AI will support the commitment to help oncology departments to receive the highest quality, guideline-based, deep learning radiotherapy solution throughout Turkey. MVision AI’s team will be working closely with SERES Medical to guarantee the distribution of timely, consistent, and GDPR compliant radiotherapy services. 

“We are pleased to announce our partnership with MVision. We believe the AI segmentation solution will become a golden standard in radiotherapy daily routines. The power of this tool will bring standardization and consistency for organ-at-risk contouring while hours of manual work will convert into an automated process that will only take minutes.” said Tolga Sengezer, partner at SERES Medical.

“With this partnership, MVision is accelerating growth to  international markets and ushering in a new era of standardization of contouring all over the world. We welcome SERES to join our mission to provide fast, reliable and high-quality AI segmentation solutions for cancer patients undergoing radiotherapy,” said Mahmudul Hasan, CEO and co-founder of MVision AI.  ‘

For further information on SERES Medical:

SERES Medical Logo MVision AI

Seres Medical Consultancy

Website: http://www.seresmed.com.tr 

Tel: +90 312 219 63 11

LinkedIn: https://www.linkedin.com/company/seres-medical-consultancy/

 

To learn more about MVision AI: 

c/o Terkko Health Hub, Haartmaninkatu 4, 00290 Helsinki, Finland.

Tel: +358 (0) 40 5489 229

Website: https://www.mvision.ai 

Email: info@ mvision.ai 

LinkedIn: https://fi.linkedin.com/company/mvisionai 

 

For media inquiries:

Tel: +358 40 500 7915

Email: pr@mvision.ai

Previous Post
What is the Current State of Cancer Care in Spain?
Next Post
Docrates, the Leading Finnish Cancer Center that Enabled the Same-Day Treatment Program with MVision AI
Sign up for newsletter

    Menu